EZZ Life Sciences secures $10 million exclusive global distribution deal with Aumake
EZZ Life Science Holdings (ASX: EZZ) has entered a 4-year exclusive global distribution agreement with Aumake Limited (ASX: AUK) targeting minimum sales of $10 million. The EZZ Life Sciences Global Distribution Agreement covers key EZZ products including EZZ Glutathione Health Support, EZZ Vitality Boost, and EZZ Sleep, with scope to expand to additional co-developed products specifically designed for China market demand.
Aumake brings proven distribution credentials to the partnership, having recorded $2.1 million in nutraceutical sales since 2025 across B2B ($1.6 million) and B2C ($0.5 million) channels. The global exclusive arrangement includes a cooperative manufacturing model designed to ensure healthy margins, with sales and marketing driven through Aumake’s established e-commerce platforms and B2B distribution network.
The agreement sets out minimum sales targets of $2.5 million per year for four years. This locked-in distribution channel provides (ASX: EZZ) with guaranteed minimum revenue commitments and access to Aumake’s established China market infrastructure, eliminating the capital burden of building direct distribution capabilities in Asia’s largest consumer market.
Key terms of the distribution agreement
The commercial structure balances exclusivity with performance accountability. Under the agreement, Aumake holds global exclusive distribution rights across all channels for covered products, whilst EZZ retains full ownership and control of intellectual property and branding. Failure to meet either the aggregate minimum sales requirement or the annual minimum sales requirement triggers automatic termination of the worldwide exclusive rights.
| Term | Detail |
|---|---|
| Territory | Global exclusive |
| Duration | 4 years |
| Minimum sales | $2.5 million per year / $10 million total |
| Brand & IP | EZZ retains full ownership and control |
| Termination | Automatic if minimums not met |
The cooperative manufacturing model mentioned in the announcement allows EZZ to maintain brand control whilst leveraging Aumake’s distribution infrastructure. This structure ensures healthy margins for both parties, with Aumake handling sales and marketing execution through its proven channels.
The automatic termination clause ensures EZZ only maintains this partnership if it delivers results, whilst the exclusivity provides distribution security during the initial four-year term. For EZZ shareholders, this performance-linked structure mitigates execution risk whilst providing guaranteed minimum revenue visibility.
Understanding exclusive distribution agreements in nutraceuticals
An exclusive distribution agreement grants a single distributor the sole right to sell specified products within defined territories or channels. For EZZ, this means Aumake becomes the only authorised global distributor for the covered product range, preventing competing distribution arrangements that could fragment market positioning or create channel conflict.
The cooperative manufacturing model referenced in the announcement allows EZZ to maintain quality control and brand ownership whilst leveraging Aumake’s established e-commerce platforms and B2B distribution network. This is particularly valuable for China market access, where Aumake’s existing infrastructure provides ready distribution capability without requiring EZZ to build direct operations in a complex regulatory environment.
For EZZ shareholders, this model provides market expansion without the capital burden of building direct distribution infrastructure in China. The exclusive arrangement also ensures Aumake has strong commercial incentive to prioritise EZZ products, as they cannot distribute competing brands within the covered categories during the agreement term.
Why nutraceuticals represent a high-margin opportunity
Nutraceuticals are the highest-margin segment within Aumake’s Nutritionals products channel, positioning EZZ products in a premium distribution environment. The agreement leverages Aumake’s proven dual-channel model:
-
B2C e-commerce platforms: Direct-to-consumer sales through established online channels
-
B2B distribution network: Wholesale supply to retailers and commercial partners
-
Premium positioning: High-margin focus aligns with EZZ’s brand positioning
This dual-channel approach maximises market reach whilst maintaining the margin structure critical for both distribution economics and EZZ’s revenue realisation.
Strategic outlook and expansion potential
The agreement includes scope for co-development of new products specifically designed for China market demand, creating a pipeline for future product expansion beyond the initial portfolio. This positions the partnership as a platform for organic growth rather than a static distribution arrangement limited to existing SKUs.
Aumake Chairman Dr Anthony Noble framed the agreement as proof of concept for broader commercial expansion:
Aumake Chairman Dr Anthony Noble
“Successfully completing and executing this distribution partnership with EZZ and, we hope, far surpassing the minimum value in the contract, will serve as a proof point for other brands to collaborate with us in the Chinese e-commerce and B2B / retail distribution markets.”
Aumake has sought shareholder approval to rebrand as Xenitra (ASX: XEN), reflecting broader ambitions in terms of products, markets, and value generation. EZZ products are positioned to benefit from this expanded Xenitra platform offering in 2026.
The agreement structure allows for organic growth beyond the $10 million minimum if market reception proves strong. The 4-year initial term with co-development provisions creates a framework for sustained commercial collaboration tailored to China market demand, whilst the performance-linked exclusivity ensures EZZ retains strategic flexibility if execution falls short of expectations.
About EZZ Life Sciences
EZZ Life Science Holdings (ASX: EZZ) is a life science company focused on consumer health through e-commerce and distribution across Australia, New Zealand, China, and globally. The company’s omnichannel distribution model aligns with this partnership structure, enabling product reach across both B2C and B2B channels through Aumake’s established infrastructure.
Want the Next Consumer Health Winner in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX news delivered within minutes of release, complete with in-depth analysis. Big News Blast alerts cover Tech, Healthcare, Finance, Consumer, and Manufacturing sectors the moment market-moving announcements drop. Click the “Free Alerts” button to start receiving real-time coverage before the market moves.